Last reviewed · How we verify
D012, placebo of D064, placebo of D701 — Competitive Intelligence Brief
phase 3
Small molecule
Live · refreshed every 30 min
Target snapshot
D012, placebo of D064, placebo of D701 (D012, placebo of D064, placebo of D701) — Chong Kun Dang Pharmaceutical. D012 is a placebo control formulation with no active pharmacological mechanism.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| D012, placebo of D064, placebo of D701 TARGET | D012, placebo of D064, placebo of D701 | Chong Kun Dang Pharmaceutical | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- D012, placebo of D064, placebo of D701 CI watch — RSS
- D012, placebo of D064, placebo of D701 CI watch — Atom
- D012, placebo of D064, placebo of D701 CI watch — JSON
- D012, placebo of D064, placebo of D701 alone — RSS
Cite this brief
Drug Landscape (2026). D012, placebo of D064, placebo of D701 — Competitive Intelligence Brief. https://druglandscape.com/ci/d012-placebo-of-d064-placebo-of-d701. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab